Atossa Genetics Inc. (NASDAQ:ATOS) Files An 8-K Submission of Matters to a Vote of Security Holders

77

Atossa Genetics Inc. (NASDAQ:ATOS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders

On April 12, 2018, the Company held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). The following items of business were considered and voted upon at the Annual Meeting: (1) the election of two Class III directors named in the proxy statement related to the Annual Meeting; (2) the ratification of the selection of BDO USA LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018; (3) the approval to increase authorized shares under Atossa Genetics 2010 Stock Option and Incentive Plan by 6,000,000 shares; (4) approval of an amendment (in the event it is deemed by the Atossa’s Board of Directors to be advisable) to Atossa’s certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Atossa’s common stock at a ratio within the range of 1:3 up to a split of 1:15, as determined by the Atossa’s Board of Directors; (5) the approval of an amendment to the certificate of incorporation to increase the number of authorized shares of common stock by 100,000,000 shares; (6) to conduct an advisory (non-binding) vote on the compensation of our named executive officers as described in the proxy statement related to the Annual Meeting; (7) an advisory (non-binding) vote on the frequency of future advisory votes on executive compensation; and (8) the transaction of any other business that may properly come before the meeting or any adjournment thereof.

The number of shares of common stock entitled to vote at the Annual Meeting was 31,822,741. The number of shares of common stock present or represented by valid proxy at the annual meeting was 23,073,057. All proposals passed except proposals 4 and 5. The number of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the Annual Meeting, other than proposals 4 and 5, are set forth below:

(i) Election of two Class III Directors

The stockholders elected two Class III directors as set forth below:

Nominee Votes For Votes Withheld

Broker

Non-Votes

Shu-Chih Chen 6,455,645 1,320,215 15,297,197
Lawrence Remmel 6,449,833 1,326,027 15,297,197
(ii) Ratification of Auditors

The stockholders ratified the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 as set forth below:

Votes For Votes Against Abstain

Broker Non-Votes

20,425,441 1,097,055 1,550,561
(iii) Increase Authorized Shares under Option Plan

The stockholders approved an increase of 6,000,000 shares to the option plan as follows:

Votes For Votes Against Abstain

Broker Non-Votes

5,257,123 2,349,198 169,539 15,297,197
(iv) Non-binding Vote on Executive Compensation

The stockholders approved an advisory non-binding vote on executive compensation as follows:

Votes For Votes Against Abstain

Broker Non-Votes

4,828,179 2,717,507 230,174 15,297,197
(v) Non-binding Vote on Frequency of Say-on-Pay

The stockholders approved an advisory non-binding vote on the frequency of the vote on executive compensation as follows:

Annual Biennial Triennial Abstain Broker Non-Votes
5,438,719 1,379,973 371,487 585,681 15,297,197

At the time of the 2018 Annual Meeting, there were insufficient votes to pass proposal 4 to authorize the reverse split in a range of 1:3 to 1:15, and proposal 5 to increase the authorized shares of common stock by 100,000,000 shares. Given the importance of these proposals, the meeting was adjourned to allow additional time for voting on these proposals. The meeting will reconvene at 1 p.m. PDT on April 19, 2018 at 107 Spring Street, Seattle, Washington 98104. During the period of adjournment the Company will continue to accept stockholder votes on these proposals.

* * *


About Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.

An ad to help with our costs